Form 4: Lexeo Therapeutics Director Steven Altschuler Granted Stock Options

Director Steven Altschuler receives stock options in Lexeo Therapeutics, signaling continued involvement with the company.

Summary

• Steven Altschuler, a director of Lexeo Therapeutics, was granted stock options on June 25, 2024.
• The options allow him to purchase 18,000 shares of Lexeo Therapeutics common stock at an exercise price of $16.87 per share.
• The options vest on the earlier of June 25, 2025, or the date of the Issuer's next annual stockholders meeting, contingent upon continuous service.
• Altschuler also signed a Power of Attorney on June 26, 2024, authorizing certain individuals to file SEC forms on his behalf.

Sentiment

Score: 7

Explanation: The document reflects a standard corporate action (stock option grant) and Power of Attorney, suggesting a neutral to slightly positive sentiment due to the alignment of director interests with the company's success.

Positives

• The grant of stock options to a director can be seen as a positive sign, aligning the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company.

Future Outlook

The document does not contain specific forward-looking statements, but the stock option grant suggests an expectation of continued service from the director.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company. This is a standard compensation practice.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like BioMarin, Sarepta Therapeutics, and Vertex Pharmaceuticals also utilize stock options to incentivize their directors and officers.
• The vesting schedule and exercise price are typical for such grants, aligning with industry norms for incentivizing long-term performance.

Stakeholder Impact

• Shareholders may view the stock option grant positively, as it aligns the director's interests with the company's performance.
• Employees may see it as a sign of stability and commitment from the leadership.

Key Dates